Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
Subscribe To Our Newsletter & Stay Updated
